NovoCure Limited

NVCR

JE00BYSS4X48

Medical Equipment, Supplies & Distribution

Delayed Nasdaq Other stock markets 20:45:10 20/09/2024 BST			5-day change	1st Jan Change
17.59 ^USD	-1.40%		-5.28%	+17.82%

09-03	NovoCure CEO Asaf Danziger to Retire, CFO Ashley Cordova Named Successor	MT
09-03	Novocure Announces CEO Changes, Effective January 1, 2025	CI

NovoCure Limited(NasdaqGS:NVCR) dropped from Russell 1000 Index

July 30, 2024

Latest news about NovoCure Limited

NovoCure CEO Asaf Danziger to Retire, CFO Ashley Cordova Named Successor	09-03	MT
Novocure Announces CEO Changes, Effective January 1, 2025	09-03	CI
Novocure Announces Management Changes	09-03	CI
NovoCure Q2 Loss Narrows, Net Revenue Increases	07-25	MT
NovoCure Limited, Q2 2024 Earnings Call, Jul 25, 2024	07-25
Earnings Flash (NVCR) NOVOCURE Posts Q2 Revenue $150.4M, vs. Street Est of $135.8M	07-25	MT
Earnings Flash (NVCR) NOVOCURE Reports Q2 Loss $-0.31 Per Share, vs. Street Est of Loss $-0.40 Per Share	07-25	MT
NovoCure Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	07-25	CI
NovoCure Limited(NasdaqGS:NVCR) dropped from Russell Midcap Growth Index	06-30	CI
NovoCure Limited(NasdaqGS:NVCR) dropped from Russell 1000 Index	06-30	CI
NovoCure Limited(NasdaqGS:NVCR) added to Russell 2000 Index	06-30	CI
NovoCure Limited(NasdaqGS:NVCR) added to Russell 2000 Growth Index	06-30	CI
NovoCure Limited(NasdaqGS:NVCR) dropped from Russell Midcap Index	06-30	CI
NovoCure Limited(NasdaqGS:NVCR) added to Russell 2000 Dynamic Index	06-30	CI
NovoCure Limited(NasdaqGS:NVCR) dropped from Russell 1000 Growth Index	06-30	CI
NovoCure Limited(NasdaqGS:NVCR) dropped from Russell 1000 Dynamic Index	06-30	CI
Wedbush Adjusts Price Target on NovoCure to $24 From $21, Maintains Neutral Rating	06-04	MT
Novocure Announces the Presentation of Clinical Data from the Phase 3 Metis Trial	06-03	CI
Novocure Releases Topline Efficacy and Safety Data from the TIGER Study Investigating the Use of Tumor Treating Fields Therapy in the Treatment of Patients with Newly Diagnosed Glioblastoma in Germany	05-23	CI
NovoCure Shares Steady After Reporting Narrower Q1 Loss, Higher Revenue	05-02	MT
BioPharma Credit Enters $400 Million Loan Agreement with Novocure Luxembourg	05-02	MT
BioPharma Credit agrees USD400 million loan for oncology firm Novacure	05-02	AN
NovoCure Limited, Q1 2024 Earnings Call, May 02, 2024	05-02
Earnings Flash (NVCR) NOVOCURE Reports Q1 Revenue $138.5M, vs. Street Est of $131.5M	05-02	MT
NovoCure Limited Reports Earnings Results for the First Quarter Ended March 31, 2024	05-02	CI

NovoCure Limited is a global oncology company. The Company is engaged in the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune and Optune Lua for the treatment of solid tumor cancers. Its commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, malignant pleural mesothelioma and pleural mesothelioma. It is conducting pivotal studies evaluating the use of TTFields in the treatment of ovarian cancer, brain metastases from non-small cell lung cancer (NSCLC) (brain metastases) and pancreatic cancer. Its key priorities are to drive commercial adoption of Optune, its commercial TTFields device. It also has a license to market Optune in China, Hong Kong, Macau and Taiwan. It has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer and ovarian cancer.

Employees

1,453

Sector

Medical Equipment, Supplies & Distribution

Calendar

23/10/2024 - Q3 2024 Earnings Release (Projected)

More about the company